Onkologie 2020: 14(Suppl.F): 159-163 | DOI: 10.36290/xon.2020.088
Complete response to pembrolizumab in a patient with stage IV NSCLC (non-small cell lung cancer)
- Pneumologická klinika Thomayerovy nemocnice a 1. LF UK, Praha
Immunotherapy is treatment that uses a person's own immune system to fight cancer. Pembrolizumab is a humanized IgG4 monoclonal antibody that targets the PD-1 receptor (Programmed cell death protein 1 receptor). Pembrolizumab demonstrated efficacy as first-line therapy for metastatic NSCLC. In the Czech Republic, pembrolizumab monotherapy has reimbursement as the first-line treatment of metastatic NSCLC in adults whose tumours express PD-L1 ≥ 50 %, with no EGFR or ALK positive tumour mutations in case of nonsquamous NSCLC. This year, there is new pembrolizumab reimbursement in combination with chemotherapy, as the first-line treatment of metastatic NSCLC in adults whose tumours express PD-L1 1-49 %, with no EGFR or ALK positive tumour mutations in case of nonsquamous NSCLC. We report the case of a 69-year-old male patient who presented with metastatic NSCLC. The patient received pembrolizumab monotherapy and there is complete response to pembrolizumab. The patient developed immune-mediated colitis successfully treated with mesalazine.
Keywords: stage IV NSCLC (non-small cell lung cancer), immunotherapy, pembrolizumab, KEYNOTE-024, immune - mediated colitis, mesalazin.
Published: November 19, 2020 Show citation
References
- Skřičková J, Kolek V. Základy moderní pneumoonkologie. Praha: Maxdorf, 2017: 560 s.
- Mapování epidemiologické situace nemalobuněčného karcinomu plic a obraz léčebné péče v ČR s důrazem na léčbu neresekovatelného a metastatického stadia v letech 2007-2013. [cit. 20.10.2020]. Dostupné z: https://www.icop.cz/res/file/odborne-zpravy/nsclc-epidemiologie-lecba-20160401.pdf.
- Imunoonkologické léky/regulátory kontrolního bodu >> Linkos.cz. Linkos: Česká onkologická společnost České lékařské společnosti J. E. Purkyně >> Linkos.cz [online]. Copyright © 2019 ČOS ČLS JEP [cit. 04.09.2019]. Dostupné z: https://www.linkos.cz/slovnicek/imunoonkologicke-leky-regulatory-kontrolniho-bodu/.
- KEYTRUDA, 50MG INF PLV CSL 1, Státní ústav pro kontrolu léčiv. Státní ústav pro kontrolu léčiv [online]. Copyright © 2001 [cit. 04.09.2019]. Dostupné z: http://www.sukl.cz/modules/medication/detail.php?code=0210911&tab=texts.
- Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024) - Full Text View - ClinicalTrials.gov. Home - ClinicalTrials.gov [online]. Dostupné z: https://clinicaltrials.gov/ct2/show/NCT02142738.
- Reck M, Rodríguez-Abreu D, Robinson AG, Hui R , Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR; KEYNOTE-024 Investigators. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016 Nov 10; 375(19): 1823-1833
Go to original source... 
Go to PubMed... - Brahmer JR, et al. Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325.